Please use this identifier to cite or link to this item:
|Title:||Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.|
|Epworth Authors:||Harewood, Laurence|
|Other Authors:||Anton, Angelyn|
|Keywords:||Prostate-Specofic Membrane Antigen|
Metastatic Prostate Cancer
Upfront Chemohormonal Therapy
Epworth Cancer Services Clinical Institute
Epworth Urology and Vascular Clinical Institute
|Citation:||BJU Int . 2020 Oct;126(4):433-435|
|Abstract:||Our study investigated the use of Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET/CT) in patients with metastatic prostate cancer who received upfront chemohormonal therapy. The aim was to compare metabolic response assessed by PSMA PET/CT with the established favourable prognostic marker of PSA ≤0.2 ng/mL following chemotherapy.|
|Journal Title:||BJU International|
|Affiliated Organisations:||Walter and Eliza Hall Institute, Melbourne, Vic., Australia.|
Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
Healthcare Imaging Services, Melbourne, Vic., Australia.
ICON Cancer Care, Melbourne, Vic., Australia.
Royal Melbourne Hospital, Melbourne, Vic., Australia.
Australian Prostate Centre, Melbourne, Vic., Australia.
Department of Surgery, University of Melbourne, Melbourne, Vic., Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.
|Type of Clinical Study or Trial:||Cohort Study|
|Appears in Collections:||UroRenal, Vascular|
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.